Paolo A. Ascierto: The history of melanoma is changing!
Paolo A. Ascierto, Director Department of Melanoma/Skin Cancers, Cancer Immunotherapy and Development Therapeutics at IRCCS, recently posted on LinkedIn.
“Few days ago at the ESMO23 conference we reported the data from CheckMate 328, the study that evaluated adjuvant therapy for melanoma in stages 2B, 2C and resected stages comparing two groups for a period of one year. The first group was randomized to receive nivolumab, while the second group, as an active control arm, was treated with ipilimumab.
The data we have reported are the result of a 7 and a half year follow up, the longest among phase three adjuvant clinical trials. Well, the results confirm the superiority of nivolumab in terms of recurrence-free survival (RFS) and distant metastasis-free survival (DMFS). The strength is 0.74 for RFS, i.e. the risk of recurrence shows a reduction of 26%, and 0.76 for DMFS, i.e. the risk of the appearance of distant metastases is reduced by 24%.
There is also another piece of data in favor of nivolumab, progression-free survival 2 (PFS2): nivolumab shows that it protects the patient more effectively from the time of the first progression to the second progression.
Although the overall survival and melanoma-specific survival data are comparable between the two study groups, the better results of nivolumab in terms of RFS, DMFS and PFS2 obtained with a follow-up of 7.5 years support its use in these patients, of which 70% are alive at the end of the period under analysis. The history of melanoma is changing!”
Read more here.
Source: Paolo A. Ascierto/LinkedIn
-
Dec 8, 2023, 17:10 | OpinionAaron Goodman: Let’s stop giving many cured young patients neuropathy
-
Dec 8, 2023, 16:29 | BlogBecome a SIOP member today or renew for 2024 membership year - SIOP
-
Dec 8, 2023, 15:51 | BlogSharon Kapambwe: Standing on the shoulders of giants- Professor Lynnette Denny
-
Dec 8, 2023, 12:47 | InsightTalha Badar: A few selected ALL abstracts to watch for at ASH23
-
Dec 9, 2023, 04:44President Biden: It's good for the millions of Americans who can't afford their medications
-
Dec 8, 2023, 17:40Ibrahim Halil Sahin: A common question I received after my tweet on the PEGASUS trial...
-
Dec 8, 2023, 17:32Daniel Stover: Tumor genomic testing (TGT) is standard for MBC patients
-
Dec 8, 2023, 12:47Talha Badar: A few selected ALL abstracts to watch for at ASH23
-
Dec 8, 2023, 12:40Amar Kelkar: We hope putting out independent cost-effectiveness analyses like this will encourage others to join
-
Dec 8, 2023, 16:33Big thank you to Dr. Rucha Kiran Patil for sharing their experiences and learnings on writing abstracts and poster presentations - Novo Nordisk Haemophilia Foundation
-
Dec 6, 2023, 14:57Tracy Gosselin: Jennifer Petruno Receives DAISY Award for Extraordinary Nurses
-
Dec 3, 2023, 16:34Tedros Adhanom Ghebreyesus: Grateful to Namibia’s Prime Minister Saara Kuugongelwa-Amadhila for her commitment to health
-
Dec 2, 2023, 18:08100 Influential Celebrities in Oncology: The 2023 Edition – Part 5
-
Dec 2, 2023, 16:50Mara Antonoff: When your famous friends come back to visit their humble beginnings
-
Dec 4, 2023, 16:26SIOP 2023 by Numbers! - International Society of Paediatric Oncology
-
Dec 2, 2023, 16:43In our recent survey, nearly 1,700 ASCO members shared feedback on the ABIM MOC requirements - ASCO
-
Nov 28, 2023, 17:34The International Association of Cancer Registries annual conference - IARC
-
Nov 26, 2023, 18:05Submit your abstract by 13 February for ESMO-Breast-24 - ESMO
-
Nov 26, 2023, 17:58Lisa A. Lacasse: My sincere gratitude to the ACS CAN team, our incredible volunteers, and supporters for another outstanding year
-
Dec 8, 2023, 17:54Dana-Farber News congratulates Sara Tolaney on receiving the Susan G. Komen 2023 Rising Star Researcher Award
-
Dec 8, 2023, 17:35Timothy M. Pawlik: Excited to announce Samilia Obeng-Gyasi as THE inaugural Endowed Surgical Professor in Health Equity
-
Dec 7, 2023, 18:30Dinesh Pendharkar is appointed as an Adjunct Professor at Roswell Park Comprehensive Cancer Center
-
Dec 7, 2023, 04:37Karun Neupane: Dreams do come true. I am going to Moffitt Cancer Center to become a hematologist/oncologist!
-
Dec 6, 2023, 16:21Sandra L. Wong has been appointed the next Dean of Emory University School of Medicine and chief academic officer for Emory Healthcare - Emory School of Medicine